Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:BLUENASDAQ:BOLDNASDAQ:CRSPNASDAQ:HALO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.19-0.8%$1.27$0.86▼$3.78$260.29M0.313.26 million shs1.38 million shsBLUEbluebird bio$4.97$4.69$3.20▼$28.60$48.67M0.27443,151 shsN/ABOLDBoundless Bio$1.06-54.1%$59.97$1.00▼$4.72$23.95M-1.34100,927 shs96,520 shsCRSPCRISPR Therapeutics$52.16+0.9%$40.68$30.04▼$63.68$4.51B1.821.89 million shs1.84 million shsHALOHalozyme Therapeutics$54.05+0.4%$55.49$42.01▼$70.51$6.65B1.151.75 million shs868,065 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%+0.85%-7.75%-17.36%-42.79%BLUEbluebird bio0.00%0.00%0.00%+0.40%-72.82%BOLDBoundless Bio0.00%+1.44%-12.45%-19.16%-75.12%CRSPCRISPR Therapeutics0.00%+9.82%+37.07%+59.74%-3.24%HALOHalozyme Therapeutics0.00%+3.52%+0.37%-9.57%+3.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.0282 of 5 stars4.51.00.00.00.63.30.6BLUEbluebird bio2.1495 of 5 stars3.10.00.00.01.41.71.3BOLDBoundless Bio2.3635 of 5 stars3.12.00.00.00.01.71.3CRSPCRISPR Therapeutics3.0225 of 5 stars4.31.00.00.01.92.50.6HALOHalozyme Therapeutics4.8528 of 5 stars3.11.00.04.42.62.54.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44609.62% UpsideBLUEbluebird bio 2.25Hold$44.60797.38% UpsideBOLDBoundless Bio 2.25Hold$4.00279.15% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7537.57% UpsideHALOHalozyme Therapeutics 2.17Hold$61.9014.52% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, ALLO, HALO, BLUE, and BOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/2/2025BOLDBoundless BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/29/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.005/28/2025BOLDBoundless BioLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$15.00 ➝ $3.005/27/2025BOLDBoundless BioLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/21/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.005/20/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K13,014.44N/AN/A$2.01 per share0.59BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14BOLDBoundless BioN/AN/AN/AN/A$6.76 per shareN/ACRSPCRISPR Therapeutics$37.31M120.72N/AN/A$22.64 per share2.30HALOHalozyme Therapeutics$1.02B6.56$4.66 per share11.61$2.86 per share18.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.23N/AN/AN/AN/A-52.98%-41.28%8/6/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%8/12/2025 (Estimated)BOLDBoundless Bio-$65.36MN/AN/AN/AN/AN/A-41.60%-34.53%N/ACRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)HALOHalozyme Therapeutics$444.09M$3.7614.388.690.3644.76%136.91%26.05%8/5/2025 (Estimated)Latest CRSP, ALLO, HALO, BLUE, and BOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/9/2025Q1 2025BOLDBoundless Bio-$0.68-$0.71-$0.03-$0.71N/AN/A5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98$1.11+$0.13$0.93$231.21 million$264.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ABOLDBoundless BioN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.719.71BLUEbluebird bio0.370.510.33BOLDBoundless Bio0.3522.1522.15CRSPCRISPR TherapeuticsN/A15.6415.64HALOHalozyme Therapeutics3.138.397.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%BLUEbluebird bio87.43%BOLDBoundless BioN/ACRSPCRISPR Therapeutics69.20%HALOHalozyme Therapeutics97.79%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%BLUEbluebird bio1.40%BOLDBoundless Bio21.10%CRSPCRISPR Therapeutics4.30%HALOHalozyme Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million189.86 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableBOLDBoundless Bio20722.39 million17.66 millionNo DataCRSPCRISPR Therapeutics46086.36 million82.65 millionOptionableHALOHalozyme Therapeutics390123.22 million120.26 millionOptionableCRSP, ALLO, HALO, BLUE, and BOLD HeadlinesRecent News About These CompaniesMoody Aldrich Partners LLC Has $6.17 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 4 at 6:43 AM | marketbeat.comHALO - Halozyme Therapeutics Inc Valuation - MorningstarJuly 3 at 6:51 PM | morningstar.comMWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-TermJuly 3 at 10:51 AM | zacks.comMeritage Portfolio Management Buys Shares of 101,651 Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3 at 8:07 AM | marketbeat.comNovem Group Acquires 4,821 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 3 at 6:28 AM | marketbeat.comOppenheimer & Co. Inc. Takes $625,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)July 1, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of HALO Q1 EarningsJuly 1, 2025 | americanbankingnews.comHalozyme Therapeutics Added to Russell 1000® IndexJune 30, 2025 | prnewswire.comHere's Why Halozyme Therapeutics (HALO) is a Strong Value StockJune 30, 2025 | zacks.comZacks Research Issues Pessimistic Forecast for HALO EarningsJune 30, 2025 | marketbeat.comArtemis Investment Management LLP Purchases Shares of 125,652 Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 28, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Spire Wealth ManagementJune 28, 2025 | marketbeat.comHalozyme Therapeutics Inc (RV7.SG)June 26, 2025 | uk.finance.yahoo.comVictory Diversified Stock Fund Q1 2025 CommentaryJune 26, 2025 | seekingalpha.comEnvestnet Portfolio Solutions Inc. Has $721,000 Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 26, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Sells $1,059,200.00 in StockJune 25, 2025 | insidertrades.comHelen Torley Sells 20,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockJune 24, 2025 | marketbeat.comRetirement Systems of Alabama Has $24.54 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 21, 2025 | marketbeat.comargenx gets EU nod for Vyvgart subcutaneous injectionJune 20, 2025 | msn.comHalozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)June 20, 2025 | prnewswire.comBoston Trust Walden Corp Cuts Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)June 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes Investors3 Top Dividend Stocks Analysts Are Bullish on Right NowBy Chris Markoch | June 6, 2025View 3 Top Dividend Stocks Analysts Are Bullish on Right NowThe Apple Comeback Will Be Better Than the SetbackBy Gabriel Osorio-Mazilli | July 4, 2025View The Apple Comeback Will Be Better Than the SetbackOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsBy Ryan Hasson | June 11, 2025View 3 Tech Focused ETFs to Watch as the Market Nears All-Time HighsCRSP, ALLO, HALO, BLUE, and BOLD Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.19 -0.01 (-0.83%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$1.19 0.00 (0.00%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.bluebird bio NASDAQ:BLUE$4.97 0.00 (0.00%) As of 06/2/2025bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Boundless Bio NASDAQ:BOLDAudentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.CRISPR Therapeutics NASDAQ:CRSP$52.16 +0.49 (+0.94%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$52.16 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Halozyme Therapeutics NASDAQ:HALO$54.05 +0.21 (+0.39%) Closing price 07/3/2025 03:44 PM EasternExtended Trading$54.05 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
